AbbVie entered an exclusive worldwide license agreement with I-Mab for lemzoparlimab (TJC4), an anti-CD47 monoclonal antibody designed to avoid red blood cell binding. AbbVie received global rights to develop and commercialize lemzoparlimab. I-Mab received $200M upfront and is eligible for up to $2.74B in development, regulatory, and commercial milestones plus tiered royalties.